The last US congressional session of 2010 had Colombian exporters
holding their breaths and Colombian diplomats in Washington crossing their
fingers. It was the last chance to be granted an extension of the 1991 Andean
Trade Preferences and Drug Eradication Act (Atpdea), which gives special trade
tariffs to Colombia, Ecuador and Peru in exchange for their contributions in
counter narcotics operations. Colombia's failure to secure an 18-month Atpdea
extension (until June 2012) due to opposition in the US Senate and its continued
failure to secure the ratification of the 2006 Free Trade Agreement (FTA), also
held up by that chamber, speak volumes about the uphill commercial battle facing
the South American nation.End of preview - This article contains approximately 652 words.
Subscribers: Log in now to read the full article
Not a Subscriber?
Choose from one of the following options